Page 4 - Bio Techne News Today

Bio-Techne (NASDAQ:TECH – Get Free Report) and Genfit (NASDAQ:GNFT – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Analyst Ratings This is a summary of current ratings and […]

Read independent reviews on Cultrex UltiMatrix Reduced Growth Factor Basement Membrane Extract from Bio-Techne on SelectScience

Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have been given a consensus rating of “Moderate Buy” by the ten brokerages that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price […]

Bio-Techne Corp. (TECH) announced Wednesday that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ExCellerate GMP iPSC Expansion Medium, Animal Free (CCM0036-GMP), supporting the development and manufacture of regenerative medicine and stem cell therapies.

UBS Group initiated coverage on shares of Bio-Techne (NASDAQ:TECH – Free Report) in a report published on Thursday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $80.00 price objective on the biotechnology company’s stock. A number of other equities research analysts have also recently weighed in on the stock. KeyCorp cut […]

Epoch Investment Partners Inc. lessened its holdings in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) by 4.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 31,704 shares of the biotechnology company’s stock after selling 1,591 shares during the quarter. Epoch Investment Partners Inc.’s […]

Key Insights Bio-Techne's estimated fair value is US$57.87 based on 2 Stage Free Cash Flow to Equity With US$63.58...

/PRNewswire/ -- The Market Study of Antibody Discovery Market by Phage Display from 2024 to...

US Bancorp DE lessened its holdings in Bio-Techne Co. (NASDAQ:TECH – Free Report) by 3.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 157,077 shares of the biotechnology company’s stock after selling 4,813 shares during the period. US Bancorp DE’s holdings […]

StockNews.com cut shares of Bio-Techne (NASDAQ:TECH – Free Report) from a buy rating to a hold rating in a research note published on Saturday morning. Other research analysts have also recently issued reports about the company. Royal Bank of Canada lowered their target price on Bio-Techne from $85.00 to $83.00 and set a sector perform […]